DGAP-Media / 2020-04-16 / 10:00
*Hennigsdorf/Berlin, Germany, April 16, 2020* - Diagnostics company
SphingoTec GmbH ("sphingotec", Hennigsdorf, Germany) today announced that it
has appointed Dr. Achim Plum as Managing Director and Chief Commercial
Officer (CCO) of the company. As CCO, Dr. Plum will focus on driving the
global commercialization of sphingotec's IVD solutions for novel biomarkers
for acute and critical care settings and their adoption on multiple IVD
instrument platforms, such as sphingotec's proprietary point-of-care
platform Nexus IB10 for rapid testing at the point of need.
"With sphingotec advancing to an end-to-end diagnostic solutions provider
with international presence, I am delighted to welcome Dr. Plum to our
leadership team," said Andreas Bergmann, Founder, Managing Director and CEO
of sphingotec. "Dr. Plum's extensive business experience, as well as his
broad management expertise in the diagnostics industry, will strengthen our
organization and help scale it to an integrated global commercial operation
providing unique diagnostic solutions for highly unmet needs in acute and
critical care."
Dr. Achim Plum has more than 18 years of management and commercial
experience in the diagnostics industry with a focus on innovative
diagnostics solutions, biomarker development and commercialization, and
personalized medicine. As CCO of sphingotec he is in charge of all business
and commercial operations of the company. After having worked with
sphingotec as a business advisor since May 2019, he in April 2020 joined
sphingotec full-time from a position as Executive Board Member and Chief
Business Officer of the Curetis Group, developing and commercializing
molecular diagnostic solutions for infectious diseases. Before Curetis, he
held senior management positions at Siemens Healthcare where he was
responsible for global Diagnostic and BioScience Technology & Innovation.
Prior to Siemens, Dr. Plum worked for eight years for the cancer molecular
diagnostics company Epigenomics, lastly as SVP Business & Strategy, the
molecular diagnostics that developed and commercializes the first
FDA-cleared liquid biopsy colorectal cancer screening test. Dr. Plum studied
Genetics, Cell Biology, and Biochemistry in Bonn, Germany, and Norwich UK.
He obtained his Ph.D. in Molecular Genetics from the University of Bonn in
1999.
Dr. Achim Plum commented: "I am very excited to now fully join the
sphingotec team. As an advisor to the company since May last year I got
increasingly impressed by sphingotec's biomarker innovations and the
enormous body of evidence and network of key opinion leaders supporting
their unique utility in acute and critical care. With our Nexus IB10
point-of-care testing platform, we are well-positioned to rapidly implement
our solutions in hospitals worldwide and significantly improving the
outcomes of critically ill patients by providing clinicians with actionable
and timely information."
Sphingotec's portfolio proprietary tests for the real-time assessment and
monitoring of endothelial function (IB10 sphingotest(R) bio-ADM(R)), kidney
function (IB10 sphingotest(R) penKid(R)), and cardiac depression (IB10
sphingotest(R) DPP3) is made available on its proprietary immunoassay
point-of-care platform, Nexus IB10, that also features a broad menu of
established routine tests tailored to point-of-care use. For the broad
availability of its diagnostic solutions on multiple platforms for central
laboratories, sphingotec pursues a licensing strategy with global players in
the diagnostics industry.
*About sphingotec*
sphingotec GmbH ("sphingotec"; Hennigsdorf near Berlin, Germany) develops
and markets innovative in vitro diagnostic (IVD) tests for novel and
proprietary biomarkers for the diagnosis, prediction and monitoring of acute
medical conditions, such as sepsis, acute heart failure, circulatory shock,
and acute kidney injury in order to support patient management and provide
guidance for treatment strategies. sphingotec's proprietary biomarker
portfolio includes bioactive adrenomedullin (bio-ADM(R)), a unique biomarker
for real-time assessment of endothelial function in conditions like sepsis
or congestive heart failure, Proenkephalin (penKid(R)), a unique biomarker
for real-time assessment of kidney function, and Dipeptidyl Peptidase 3
(DPP3), a unique biomarker for cardiac depression. In addition, sphingotec
develops a portfolio of novel biomarkers, which predict the risks of
developing obesity, breast cancer and cardiovascular diseases. IVD tests for
sphingotec's proprietary biomarkers are made available as sphingotest(R)
microtiterplate tests as well as point-of-care tests on the Nexus IB10
immunoassay platform by sphingotec's subsidiary Nexus Dx Inc. (San Diego,
CA, USA) alongside a broad menu of IB10 tests for established biomarkers for
acute and critical care.
*Contact *
SphingoTec GmbH
Ruxandra Lenz
Neuendorfstr. 15 A
16761 Hennigsdorf
Germany
Tel. +49-3302-20565-0
press@sphingotec.de
www.sphingotec.com
End of Media Release
Issuer: SphingoTec GmbH
Key word(s): Health
2020-04-16 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
1022757 2020-04-16
(END) Dow Jones Newswires
April 16, 2020 04:00 ET (08:00 GMT)
© 2020 Dow Jones News
